Board appointments to advance targeted protein degradation therapeutics 

PhoreMost has brought two heavyweight biotech leaders onto its board as the company advances its next-generation degrader therapeutics and gears up to commercialise its GlueSEEKER® platform.

Barbara Duncan joins as Chair, bringing decades of financial and strategic leadership experience, including a string of major exits in oncology and biopharma. Her past board roles span high-value acquisitions such as Fusion Pharmaceuticals (acquired by AstraZeneca for $2.4 billion) and Immunomedics (acquired by Gilead for $21 billion). She’s raised over $1.5 billion in financing and helped take several companies public.

Alongside her, Stephen Dilly joins as a Non-Executive Director. A clinician and biotech executive with a strong operational track record, Dilly has led multiple companies through clinical development and acquisition – notably overseeing FDA approval of Palforzia and Sierra Oncology’s $1.9 billion acquisition by GSK. He is currently CEO and Chair at Codexis.

The appointments are designed to bolster PhoreMost’s momentum as it pushes its pipeline of targeted protein degraders – an emerging drug modality with game-changing potential – into the next phase of development. The company’s GlueSEEKER platform, which enables the discovery of molecular glues for hard-to-drug targets, has recently passed key chemical translation milestones.

Founder and former Chair Dr Chris Torrance remains on the board as a Non-Executive Director.

“Barbara and Stephen bring outstanding insight and experience to PhoreMost as we sharpen our commercial focus and accelerate development of differentiated degrader assets,” said CEO Dr Neil Torbett. “Their leadership comes at a pivotal moment.”

More information online